Answers are grounded in this paper and cite their sources.
Clinical analysis reveals increased mortality in immunosuppressed COVID-19 ICU patients, highlighting the need for tailored therapeutic strategies.
Critical immunosuppressed patients with COVID-19 have higher mortality, particularly transplant recipients. Tocilizumab shows potential benefits for IS patients. These findings highlight the need for tailored therapeutic strategies for immunosuppressed individuals with severe COVID-19. Further research is needed to confirm these results in the current clinical context.
No takes yet. Share an insight, caveat, or question.
Galli et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: